inclusion criteria: * ≥18 years * males and females * confirmed clinical diagnosis of covid-19 positive by real-time reverse transcription polymerase chain reaction (rt-pcr) and/or sars-cov-2 antigen test performed 120 hours prior to patient inclusion in the study * ldh 250-400 u/l * acceptance of informed consent signature * imc: 18.5-30 * patients not participating in other trials * no hepatic and renal disorders * possession of mental faculties to participate in the study

inclusion criteria: * ≥18 years * males and females * confirmed clinical diagnosis of covid-19 positive by real-time reverse transcription polymerase chain reaction (rt-pcr) and/or sars-cov-2 antigen test performed 120 hours prior to patient inclusion in the study * ldh 250-400 u/l * acceptance of informed consent signature * imc: 18.5-30 * patients not participating in other trials * no hepatic and renal disorders * possession of mental faculties to participate in the study

inclusion criteria: - ≥18 years - males and females - confirmed clinical diagnosis of covid-19 positive by real-time reverse transcription polymerase chain reaction (rt-pcr) and/or sars-cov-2 antigen test performed 120 hours prior to patient inclusion in the study - ldh 250-400 u/l - acceptance of informed consent signature - imc: 18.5-30 - patients not participating in other trials - no hepatic and renal disorders - possession of mental faculties to participate in the study

inclusion criteria: - ≥18 years - males and females - confirmed clinical diagnosis of covid-19 positive by real-time reverse transcription polymerase chain reaction (rt-pcr) and/or sars-cov-2 antigen test performed 120 hours prior to patient inclusion in the study - ldh 250-400 u/l - acceptance of informed consent signature - imc: 18.5-30 - patients not participating in other trials - no hepatic and renal disorders - possession of mental faculties to participate in the study